Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
RAS wild-type
Associations
(17)
News
Trials
A1 | Sensitive
A2 | Sensitive
B | Sensitive
C2 | Sensitive
C3 | Sensitive
A1 | Resistant
A2 | Resistant
B | Resistant
C2 | Resistant
C3 | Resistant
Show legend
Drug categories
Tyrosine Kinase Inhibitors
EGFR
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Immunotherapy
PARP Inhibitors
Cancel
Colorectal Cancer
Colon Cancer
panitumumab + niraparib
C3
RAS wild-type
|
Colorectal Cancer
|
panitumumab + niraparib
panitumumab
A1
RAS wild-type
|
Colorectal Cancer
|
panitumumab
cetuximab
A2
RAS wild-type
|
Colorectal Cancer
|
cetuximab
C3
RAS wild-type
|
Colon Cancer
|
cetuximab
fruquintinib
B
RAS wild-type
|
Colorectal Cancer
|
fruquintinib
bevacizumab
B
RAS wild-type
|
Colorectal Cancer
|
bevacizumab
ramucirumab
C2
RAS wild-type
|
Colorectal Cancer
|
ramucirumab
bevacizumab + cetuximab
C2
RAS wild-type
|
Colorectal Cancer
|
bevacizumab + cetuximab
cetuximab + avelumab
C2
RAS wild-type
|
Colorectal Cancer
|
cetuximab + avelumab
cetuximab + camrelizumab
C2
RAS wild-type
|
Colorectal Cancer
|
cetuximab + camrelizumab
panitumumab + cabozantinib tablet
C3
RAS wild-type
|
Colorectal Cancer
|
panitumumab + cabozantinib tablet
regorafenib
A1
RAS wild-type
|
Colorectal Cancer
|
regorafenib
avelumab
C3
RAS wild-type
|
Colorectal Cancer
|
avelumab
anlotinib
C3
RAS wild-type
|
Colorectal Cancer
|
anlotinib
cetuximab + tislelizumab
C3
RAS wild-type
|
Colorectal Cancer
|
cetuximab + tislelizumab
EGFR inhibitor
C3
RAS wild-type
|
Colorectal Cancer
|
EGFR inhibitor
EGFR inhibitor + VEGF inhibitor
C3
RAS wild-type
|
Colorectal Cancer
|
EGFR inhibitor + VEGF inhibitor
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
